Recombinant human granulocyte colony-stimulating factor (G-CSF) has been in clinical use for approximately 2 decades. In healthy donors, it has been used to mobilize peripheral blood progenitor cells for hematopoietic stem cell transplantation and granulocytes for apheresis collection. In patients, it has been used to decrease the duration of neutropenia after chemotherapy and to offset the neutropenia due to myelodysplasia, acquired immunodeficiency syndrome, and genetic disorders of granulocyte production. As the number of uses of G-CSF in clinical practice grows, more side effects of this generally safe pharmaceutical agent are being recognized. Our objective in this article is to provide an in-depth review of the reported adverse events associated with the use of G-CSF.

中文翻译：

---

粒细胞集落刺激因子给药：不良事件。

重组人粒细胞集落刺激因子（G-CSF）已在临床中使用了大约20年。在健康的供体中，已将其用于动员外周血祖细胞用于造血干细胞移植，并用于动员粒细胞进行单采血液采血。在患者中，它已被用于减少化疗后中性粒细胞减少的持续时间，并抵消由于骨髓增生异常，获得性免疫缺陷综合症和粒细胞产生的遗传疾病引起的中性粒细胞减少。随着G-CSF在临床实践中的使用数量增加，这种公认的安全药物的副作用越来越多。本文的目的是对与使用G-CSF相关的不良事件进行深入的综述。